Available with & without DeepDx® Viewer
6 Solutions
5 Products
An algorithm that automatically detects, segments and quantifies Ki-67 expression in breast cancer.
An algorithm that automatically detects, segments and quantifies Ki-67 expression in breast cancer.
An algorithm that automatically detects, segments and quantifies Ki-67 expression in breast cancer.
An algorithm that automatically detects, segments and quantifies Ki-67 expression in breast cancer.
An algorithm that automatically detects, segments and quantifies Ki-67 expression in breast cancer.
At Deep Bio, we're at the forefront of transforming drug discovery through harnessing the full potential of data and AI. Our AI-enabled drug discovery solutions help guide biopharmaceutical companies in their quest to bring new drugs to market. DeepCDx combines state-of-the-art AI technology with a client-driven approach to develop purpose-built diagnostic solutions that accelerate the pace of discovery and drive innovation.
To Learn More Download
Our patented methods have been trained on thousands of cases to yield instantaneous and precise analysis of data.
Deep learning-based diagnostics
technology
Diagnostic result visualization
technology
Tissue slide indexing technology
Intelligent annotation technology
DeepDx Prostate won Silver at the Edison Award 2021 in the Cellular Research & Disease Prevention category.
Our research team won the first place in Camelyon17, a global image analysis competition for detection and classification of breast cancer lymph nodes metastasis.
Development of prediction models by combining cancer pathology image analysis with oncology clinical data.
DeepDx® Prostate is CE-marked, and MFDS-approved for clinical use in Korea. DeepDx® solutions are not cleared by the FDA and for Research Use Only (RUO) in the United States. Contact Deep Bio for more information on system configuration, functionality and indications for use.
